The “right-to-try” bill heads to President Trump’s desk for signing after passing the House of Representatives; the FDA said certain gene therapies in development can qualify for quicker review, starting with hemophilia; brand-name drug makers have raised prices by double-digit percentages since 2012, with 47 drugs costing Medicare and Medicaid nearly $12 billion in 2016.
The “right-to-try” bill heads to President Trump’s desk for signing after passing the House of Representatives for the second time by 250-169. The bill, which would allow terminally ill patients to bypass the FDA and request experimental drugs that have cleared phase 1 safety trials directly from drug companies, passed largely along party lines. The Senate passed the bill in August 2017, and the House approved its own version in March. That version was opposed less by medical groups, but then the legislation stalled. House leaders decided to pass the Senate version instead, The Washington Post reported.The FDA said certain gene therapies in development can qualify for quicker review, STAT reported. Commissioner Scott Gottlieb, MD, said that hemophilia is the first disease the FDA will target with its new policy. Under the new policy, gene therapies for hemophilia could be evaluated based on whether the therapy increases clotting proteins in the blood, regardless of whether the therapy actually causes the patient to bleed less.
Brand-name drug makers blamed by the Trump administration for potentially stalling generic competition have raised prices by double-digit percentages since 2012, with 47 drugs costing Medicare and Medicaid nearly $12 billion in 2016, Kaiser Health News reported. Kaiser’s analysis said the spending totals don’t include rebates, which pharmaceutical companies return to the government. The rebates ranged from 9.5% to 26.3% for Medicare Part D in 2014.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More